- Machine learning integration identified CXCL1 and IGFBP5 as core genes underlying Alzheimer's and Crohn's disease comorbidity.
- CXCL1 and IGFBP5 mediate inflammation, immune regulation, cell migration, and tissue remodelling, potentially linking gut-brain axis and IgSF CAM signalling.
- Virtual knockout, single-cell validation, and molecular docking nominate Dasatinib, Mifepristone, and Retinoic acid as candidate targeted therapies.
Psychiatry Investig. 2026 Sep 22. doi: 10.30773/pi.2026.0214. Online ahead of print.
ABSTRACT
OBJECTIVE: Alzheimer’s disease (AD) and Crohn’s disease (CD) both involve inflammation and immune dysregulation, yet the potential molecular mechanisms underlying their comorbidity remain unclear.
METHODS: We integrated transcriptomic data from AD and CD patients and applied differential expression analysis, weighted gene coexpression network analysis, protein-protein interaction networks, and multiple machine learning approaches to identify key comorbidity genes. Functional enrichment, single-cell sequencing validation, and virtual knockout analyses were used to explore their biological roles. Molecular docking was performed to evaluate the binding affinity of candidate small-molecule drugs to the identified core genes.
RESULTS: CXCL1 and IGFBP5 were identified as core comorbidity genes. CXCL1 was associated with inflammatory signaling, including cytokine receptor binding, neutrophil migration, and NOD-like receptor signaling. IGFBP5 was linked to growth factor binding, smooth muscle cell proliferation, and extracellular matrix-receptor interactions. Single-cell and virtual knockout analyses indicated that these genes play pivotal roles in inflammation, immune regulation, cell migration, and tissue remodeling, potentially bridging central and peripheral inflammation via the gut-brain axis and IgSF CAM signaling. Candidate drug prediction and molecular docking suggested that small molecules such as Dasatinib, Mifepristone, and Retinoic acid may modulate these pathways.
CONCLUSION: This study reveals the critical roles of CXCL1 and IGFBP5 in AD-CD comorbidity, providing a theoretical basis for exploring gut-brain axis mechanisms and potential targeted interventions.
PMID:42765175 | DOI:10.30773/pi.2026.0214
Share Evidence Blueprint
Save to Google Notes

Search Google Scholar
Save as PDF
⭐ My Revision List

